Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA3 | P32297 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6329514 | 0.85 | MAPT (0.49) | LMNAKDM4ECYP3A4ACHEMAPT | |
| SCHEMBL23819693 | 0.83 | CHRNA3 (0.50) | CHRNA3PPARGPPARACYP3A4MAPT | |
| SCHEMBL823757 | 0.82 | LMNA (0.52) | LMNAKDM4ECYP3A4ACHEMAPT | |
| SCHEMBL31621879 | 0.82 | LMNA (0.52) | LMNAKDM4ECYP3A4ACHEMAPT | |
| SCHEMBL473532 | 0.82 | LMNA (0.52) | CHRNA3LMNAKDM4ECYP3A4ACHE | |
| SCHEMBL27504231 | 0.82 | PPARG (0.44) | CHRNA3PPARGPPARACYP3A4MAPT | |
| SCHEMBL5260935 | 0.81 | MEN1 (0.52) | CHRNA3PPARGPPARAHTR2ASLC6A4 | |
| SCHEMBL7959618 | 0.81 | LMNA (0.47) | LMNAKDM4ECYP3A4ACHEMAPT | |
| SCHEMBL1432110 | 0.79 | ACHE (0.59) | LMNAKDM4ECYP3A4ACHEMAPT | |
| SCHEMBL29001439 | 0.79 | KDM4E (0.61) | LMNAKDM4ECYP3A4ACHEMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2148865-B1 | PYRAZOLE INHIBITORS OF WNT SIGNALING | GENENTECH INC (US) | 2017-05-17 | — | — | EP | disclosed |
| CN-103958502-B | Quinazoline compounds as serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-02-10 | — | — | CN | disclosed |
| US-9187462-B2 | Substituted quinazolines as serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-11-17 | — | — | US | disclosed |
| EP-2739618-B1 | QUINAZOLINE COMPOUNDS AS SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-09-16 | — | — | EP | disclosed |
| US-20150087664-A1 | QUINAZOLINE COMPOUNDS AS SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2015-03-26 | — | — | US | disclosed |
| CN-101952244-B | N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors | AMIRA PHARMACEUTICALS INC | 2014-11-05 | — | — | CN | disclosed |
| EP-2739618-A1 | QUINAZOLINE COMPOUNDS AS SERINE/THREONINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2014-06-11 | — | — | EP | disclosed |
| CN-102076661-B | Antagonists of prostaglandin d2 receptors | AMIRA PHARMACEUTICALS INC | 2014-04-09 | — | — | CN | disclosed |
| WO-2013020062-A1 | QUINAZOLINE COMPOUNDS AS SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2013-02-07 | — | — | WO | disclosed |
| CN-102076661-A | Antagonists of prostaglandin d2 receptors | AMIRA PHARMACEUTICALS INC | 2011-05-25 | — | — | CN | disclosed |
| CN-101952244-A | PGD 2The N of acceptor, N-disubstituted amido alkyl biphenyl antagonist | AMIRA PHARMACEUTICALS INC | 2011-01-19 | — | — | CN | disclosed |
| US-20100137394-A1 | PYRAZOLE INHIBITORS OF WNT SIGNALING | GRENENTECH, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| EP-2148865-A1 | PYRAZOLE INHIBITORS OF WNT SIGNALING | Genentech, Inc. (US) | 2010-02-03 | — | — | EP | disclosed |
| CN-101605798-A | Imidazothiazole derivative | DAIICHI SANKYO CO LTD (JP) | 2009-12-16 | — | — | CN | disclosed |
| WO-2008137408-A1 | PYRAZOLE INHIBITORS OF WNT SIGNALING | GENENTECH, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| US-20050209274-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABOTT LABORATORIES | 2005-09-22 | — | — | US | disclosed |
| CN-1203066-C | (METHYLSULFONYL) PHENYL-2- (5H) -FURANONE AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC (CA) | 2005-05-25 | — | — | CN | disclosed |
| CN-1200119-A | (METHYLSULFONYL) PHENYL-2- (5H) -FURANONE AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC (CA) | 1998-11-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209274-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | MCHR1, MCHR2, MC1R | CHRNA3 291/4885LMNA 3804/4885PPARG 2233/4885 |
| US-20100137394-A1 | PYRAZOLE INHIBITORS OF WNT SIGNALING | WNT1, WNT3A, CTNNB1 | CHRNA3 4282/4885LMNA 3768/4885PPARG 1939/4885 |
| US-20150087664-A1 | QUINAZOLINE COMPOUNDS AS SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K3, MAP3K2 | CHRNA3 3865/4885LMNA 3071/4885PPARG 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.